MT-5111 is under clinical development by Molecular Templates and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MT-5111’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MT-5111 is under development for the treatment of HER2 positive solid tumors including metastatic breast cancer, TNBC, metastatic biliary tract carcinoma, metastatic colorectal cancer, metastatic NSCLC, metastatic pancreatic cancer, metastatic uterine cancer and gastric or gastroesophageal adenocarcinomas. It acts by targeting the human epidermal growth factor receptor 2 (HER2). The drug candidate is single chain variable fragment (scFv) fused to the enzymatically active de-immunized Shiga-like toxin-A subunit (SLTA), developed based on engineered toxin bodies technology platform which is a next-generation recombinant immunotoxin scaffold based on the Shiga-like toxin A subunit.
Molecular Templates overview
Molecular Templates (MTI), formerly Threshold Pharmaceuticals, is a clinical-stage oncology company. The company discovers and develops biologic therapeutics for cancer. It’s pipeline products include MT-5111, SLAMF-7, CTLA-4, MT-0169 and MT-6402. MTI lead product MT-3724, a fusion protein, is designed for the treatment of Non-Hodgkin Lymphoma; and MT-0169 is used for the treatment of multiple myeloma. The company also develops Engineered Toxin Bodies (ETBs) for the treatment of breast cancer, melanoma and allogeneic stem cell transplantation. It develops ETBs for various targets including CD20, CD38, HER2, and PD-L1. MTI is headquartered in Austin, Texas, the US.
For a complete picture of MT-5111’s drug-specific PTSR and LoA scores, buy the report here.